MicroSalt PLC
24 September 2026
24 September 2026
MicroSalt Plc
MicroSalt("MicroSalt" or the "Company")
Notice of Interim Results and Investor Presentation
MicroSalt (AIM: SALT), a leading manufacturer of full-flavour natural salt containing approximately 50% less sodium, is pleased to announce that it will be publishing its results for the six-month period ended 30 June 2026 on Tuesday 29 September 2026.
Rick Guiney, CEO, and Gary Urmston, Interim CFO, will be hosting a live presentation via Investor Meet Company on Wednesday 30 September 2026 at 3pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 29 Sept 2026 at 09:00 BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet MICROSALT PLC via:
https://www.investormeetcompany.com/microsalt-plc/register-investor
Investors who already follow MICROSALT PLC on the Investor Meet Company platform will automatically be invited.
Enquiries:
|
MicroSalt plc |
Via Gracechurch Group |
|
Rick Guiney, CEO |
|
|
|
|
|
Zeus (Nominated adviser and broker) |
+44 (0)20 3829 5000 |
|
David Foreman / Ed Beddows (Investment Banking) |
|
|
Nick Searle (Head of Equity Capital Markets) |
|
|
|
|
|
Gracechurch Group(Financial PR) |
+44 (0)20 4582 3500 |
|
Heather Armstrong, Alexis Gore, Rebecca Scott |
|
About MicroSalt
MicroSalt is disrupting the global salt market with its patented, full-flavour, low-sodium salt designed for both food manufacturers and consumers. Using proprietary micron-sized particles, MicroSalt delivers the same salty taste as traditional salt with approximately 50% less sodium, offering a scalable solution to one of the world's most pressing health challenges.
Excess sodium consumption is a leading contributor to cardiovascular disease, the world's number one cause of death. The World Health Organisation has targeted a 30% reduction in global sodium intake by 2025, a shift projected to save seven million lives by 2030. The economic case is equally compelling: in the UK alone, cardiovascular disease costs £19 billion annually, and reducing average daily salt intake by just one gram could save over 4,000 lives and £288 million each year.
Operational since 2018, MicroSalt has established a defensible IP portfolio, holding a granted US patent and 14 pending applications worldwide. These protections create significant barriers to entry in a market expected to grow exponentially as regulation and consumer demand accelerate.
MicroSalt is ideally positioned for scale and market leadership, with clear pathways into food manufacturing, consumer channels, and ultimately the broader £10+ billion global salt market. MicroSalt is more than a healthier alternative-it is a disruptive, category-defining solution poised to deliver significant commercial and societal impact.
For more information, please visitwww.microsaltinc.comor follow on X @microSaltPLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.